Maravai LifeSciences
MRVI
150 hedge funds and large institutions have $313M invested in Maravai LifeSciences in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 52 closing their positions.
1,292% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $133K
30% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 44
7% more capital invested
Capital invested by funds: $292M → $313M (+$20.4M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.08% less ownership
Funds ownership: 92.15% → 90.07% (-2.1%)
18% less funds holding
Funds holding: 184 → 150 (-34)
62% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.63M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$5.56M |
| 3 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
+$4.55M |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.94M |
| 5 |
FPA
First Pacific Advisors
El Segundo,
California
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$7.84M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.79M |
| 3 |
Millennium Management
New York
|
-$2.37M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.77M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.46M |
MRVI Hedge Fund Activity: Q2 2025 in Review
150 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2025, worth a combined $313M — up 7% from $292M a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of MRVI and 20 opened new positions — a net loss of 32 holders — while 44 trimmed existing stakes and 57 added.
The largest buyer was UBS Group, adding an estimated $5.63M. The largest seller was Mirabella Financial Services, cutting an estimated $7.84M.
- 150 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2025, down from 184 in Q1 2025.
- Funds reported $313M of Maravai LifeSciences stock for Q2 2025, up 7% quarter-over-quarter.
- 20 funds opened new Maravai LifeSciences positions in Q2 2025 and 52 closed out, a net change of -32 holders.
- The largest Maravai LifeSciences buyer in Q2 2025 was UBS Group, an estimated $5.63M added.
- The largest Maravai LifeSciences seller in Q2 2025 was Mirabella Financial Services, an estimated $7.84M sold.
Based on aggregated 13F filings for Q2 2025.